The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

Investment Considerations VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders. Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain. The global CNS therapeutics market is … Continue reading “VistaGen Therapeutics Inc. (NASDAQ: VTGN)”

View Profile